Loading...
Publication
Systemic injections of Cannabidiol enhance Acetylcholine levels from basal forebrain in rats
| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 1.02 MB | Adobe PDF |
Advisor(s)
Abstract(s)
Cannabis sativa is a plant that contains more than 500 components, of which the most studied are Δ9-tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD). Several studies have indicated that CBD displays neurobiological effects, including wake promotion. Moreover, experimental evidence has shown that injections of CBD enhance wake-related compounds, such as monoamines (dopamine, serotonin, epinephrine, and norepinephrine). However, no clear evidence is available regarding the effects of CBD on additional wake-related neurochemicals such as acetylcholine (ACh). Here, we demonstrate that systemic injections of CBD (0, 5, 10 or 30 mg/kg, i.p.) at the beginning of the lights-on period, increase the extracellular levels of ACh collected from the basal forebrain and measured by microdialysis and HPLC means. Moreover, the time course effects on the contents of ACh were present 5 h post-injection of CBD. Altogether, these data demonstrate that CBD increases ACh levels in a brain region related to wake control. This study is the first to show the effects of ACh levels in CBD-treated rats and suggests that the basal forebrain might be a site of action of CBD for wakefulness modulation.
Description
Keywords
Cannabis Dopamine Monoamines Sleep Wakefulness
Citation
Murillo-Rodríguez, E., Arankowsky-Sandoval, G., Rocha, N. B., Peniche-Amante, R., Veras, A. B., Machado, S., & Budde, H. (2018). Systemic Injections of Cannabidiol enhance Acetylcholine levels from basal forebrain in rats. Neurochemical Research, 43(8), 1511–1518. https://doi.org/10.1007/s11064-018-2565-0
Publisher
Springer
Collections
CC License
Without CC licence